Key Takeaways Cannabis equities have slumped since 2018 amid stalled U.S. federal legalization efforts.Operators face high taxes, costly debt and limited banking access under current federal rules.Global markets and potential U.S. reform are seen as key catalysts for sector recovery.When Canada legalized recreational cannabis in 2018, many believed that the United States wouldn’t be far behind. Optimism grew further when the 2018 Farm Bill legalized hemp nationwide, fueling hopes that full federal marijuana ...

Financial Data and Key Metrics Changes - Tilray achieved record annual revenue of $821 million, a 4% increase year over year on a constant currency basis, and $834 million, a 6% increase year over year [7][34] - The company reported a gross profit of $241 million, an 8% increase year over year, and the highest gross margin at 29%, up from 28% in the prior year [8][40] - A net loss for fiscal year 2025 increased to $2.2 billion, or $2.46 per share, compared to a loss of approximately $220 million in the prior year [41][50] Business Line Data and Key Metrics Changes - International cannabis revenue reached $22.4 million in Q4, up 71% year over year, with a full year growth of approximately 20% [7][14] - The beverage segment reported net revenue of $65.6 million in Q4, a 19% year-over-year increase, although impacted by SKU rationalization initiatives [24][38] - Wellness revenue grew by 9% to over $60 million, driven by the expansion of the Manitoba Harvest brand and new product innovations [29][30] Market Data and Key Metrics Changes - In Canada, Tilray maintained a 9.3% market share in the adult recreational segment, with a total cannabis revenue of $186 million for the fiscal year [18][12] - The international cannabis business showed significant growth, particularly in Germany, where revenue grew by 134% year over year in Q4 [15][12] - The U.S. beverage division generated approximately $240 million in sales, with a focus on expanding market share in the non-alcoholic beverage sector [13][28] Company Strategy and Development Direction - The company is focused on solidifying its global leadership in cannabis and expanding its beverage and wellness business through innovation and strategic acquisitions [6][12] - Tilray aims to strengthen its balance sheet through strategic debt restructuring and has reduced its net debt to EBITDA ratio to 0.3 times from 1.7 last year [9][41] - The company is optimistic about future growth opportunities in international markets, particularly in Europe and emerging markets [17][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strategy despite recent non-cash impairment charges, emphasizing the intrinsic value of tangible assets and brand equity [11][43] - The Canadian cannabis market is stabilizing, with expectations of regulatory reforms that could enhance market conditions [17][65] - Management anticipates continued growth in international cannabis markets, particularly in Germany, Poland, and the UK, with significant plans for expansion [70][72] Other Important Information - The company implemented strategic initiatives that impacted revenue by approximately $35 million due to decisions aimed at enhancing margins and profitability [7][35] - The beverage business faced challenges due to softer consumer demand and unexpected distribution headwinds, but corrective actions are being taken to improve performance [24][26] - Tilray's wellness segment is expected to expand further in fiscal year 2026, focusing on better-for-you functional foods and beverages [31][30] Q&A Session Summary Question: What is the current status of importing rights and delays? - Management indicated that legal issues in Portugal are being resolved, and they expect to start shipping products soon, with an estimated $8 million in sales impacted by trapped shipments [60][61] Question: Can you elaborate on the Canadian market's equilibrium and price pressures? - Management noted that the Canadian market is stabilizing with more retail stores opening, leading to increased consumer preference for legal cannabis over illicit products, and potential regulatory changes could further enhance market conditions [63][65] Question: How should growth in international markets be viewed for next year? - Management expressed optimism about international growth, particularly in Germany and other European markets, with significant plans for expansion and a focus on medical cannabis [70][72]

Industry Overview - The Canadian cannabis market is gaining investor attention as the U.S. cannabis industry continues to grow rapidly, with legal cannabis sales projected to reach nearly $39 billion in 2024 and potentially exceed $44 billion in 2025 [1] - Despite the growth, federal legalization in the U.S. remains stalled, but several states are advancing their own reform efforts, which is attracting interest in Canadian companies with U.S. exposure [1] Company Highlights - **Tilray Brands Inc. (TLRY)**: - Tilray has expanded significantly in the U.S., owning over 150 dispensaries in key markets like California and Michigan, and has diversified into the wellness and THC-infused beverage sectors [4][7] - The company reported a 13% increase in net revenue to $200 million, with its cannabis segment generating $61 million at a 40% gross margin, and a 132% year-over-year growth in the beverage segment [7] - Although Tilray posted a net loss, it narrowed that loss and achieved an adjusted EBITDA of $9 million, indicating improving fundamentals [7] - **Canopy Growth Corporation (CGC)**: - Canopy operates approximately 120 dispensaries in the U.S. and owns the vaporizer company Storz & Bickel, focusing on both recreational and medical markets [8][10] - The latest quarterly report showed net revenue of around C$66 million, a slight decrease from the previous year, but gross profit rose over 65% to achieve a 35% gross margin [10] - Canopy has cut its total debt by nearly 50% over the fiscal year, reflecting a strong focus on long-term sustainability and operational efficiency [10] - **Cronos Group Inc. (CRON)**: - Cronos has a growing presence in the U.S. with distribution deals supplying products to around 80 dispensaries, focusing on cannabinoid innovation [11][13] - The company reported net revenue of over $32 million, reflecting year-over-year growth, and gross profit rose to $13.7 million due to better cost management [13] - Cronos is investing in research and development to position itself for long-term success in the competitive U.S. market [13] Strategic Insights - The three Canadian cannabis companies—Tilray, Canopy Growth, and Cronos—are strategically expanding their U.S. footprint and improving financial health, making them key players to watch as U.S. legalization discussions continue [14]

Core Viewpoint - The Story dispensary in Hoboken is resuming construction after a prolonged period of controversy and litigation, with concerns from local residents regarding its impact on the neighborhood [3][5][6]. Group 1: Background and Controversy - The Story dispensary has faced significant opposition over the past four years, including a court settlement and a petition from neighbors concerned about increased traffic [3][4]. - The dispensary's location has raised questions about potential conflicts of interest due to its ties to local politicians, particularly Mayor Steven Fulop [5][8]. - Residents initially believed the location would be used for physical therapy, leading to a lawsuit that was settled last year [6]. Group 2: Regulatory and Operational Status - Despite ongoing construction, the Story dispensary does not currently have the necessary permits to operate, putting the project at risk [9]. - The state has recently approved licenses for cannabis consumption lounges, but only a few locations have been authorized for this use so far [10]. Group 3: Community Perspectives - Some community members argue that the dispensary will not negatively impact the area more than existing bar-restaurants [7]. - A petition has been initiated by residents who believe the dispensary is poorly located [7].

Core Insights - Green Thumb Industries (GTBIF) has seen a persistent decline in its stock despite being one of the largest cannabis operators by market capitalization, primarily due to regulatory challenges and increasing competition [1][9] - The company's revenue growth appears positive, but profitability is under pressure from rising costs and pricing compression [1][10] Company Fundamentals - GTBIF's first-quarter 2025 revenue increased by only 1% year-over-year to $280 million, with a 14% growth in consumer packaged goods (CPG) partially offset by a 2.5% decline in retail sales due to price compression [3][10] - Gross profit margins fell to 51.3%, down 80 basis points from the previous year, indicating challenges in maintaining profitability [4] - Selling and operating expenses rose by 11%, and the effective tax rate increased sharply to 79% from 51% in the prior year, contributing to a significant decline in net income and earnings per share (EPS) [5] Market Conditions - The cannabis market is becoming increasingly competitive, with GTBIF facing stiff competition from peers like Aurora Cannabis, Cresco Labs, and Curaleaf Holdings, all pursuing similar strategies [7] - Competitors are expanding internationally, which provides them with an advantage over GTBIF, which remains reliant on the saturated U.S. market [8] Future Outlook - The company is expected to face continued pressure from pricing compression in maturing markets, with management anticipating flat sequential revenue growth in the second quarter and adjusted EBITDA margins likely to remain below 30% [6][10] - The investment case for GTBIF appears weak for risk-averse investors, especially given the lack of international diversification and ongoing domestic challenges [12]

Core Insights - Cannabis REITs are gaining momentum as investors seek dividend-paying stocks with long-term growth potential, with the U.S. cannabis market projected to exceed $45 billion by the end of 2025 [1][4] - The sector is benefiting from federal reclassification efforts and pro-cannabis amendments, improving investor sentiment and technical strength among several cannabis REITs [2][3] - Cannabis REITs provide a stable income stream and exposure to a rapidly growing industry, making them attractive for dividend investors [1][3] Company Summaries - **Innovative Industrial Properties, Inc. (IIPR)**: The largest cannabis REIT in the U.S., owning over 110 properties across 19 states, with a focus on long-term, triple-net lease agreements. In the most recent quarter, IIPR reported $74 million in rental revenue, a 12% year-over-year increase, and net income of $35 million, or $1.22 per share [5][8] - **NewLake Capital Partners, Inc. (NLCP)**: Owns 32 properties across 15 states, focusing on long-term leases with financially healthy cannabis businesses. In its latest quarterly report, NLCP posted $19 million in rental revenue, a 10% increase, and net income of $11 million, or $0.45 per share [9][10] - **Chicago Atlantic Real Estate Finance, Inc. (REFI)**: Specializes in lending capital to licensed cannabis operators, having deployed over $500 million across more than a dozen states. REFI reported $22 million in revenue, a 15% year-over-year increase, and net income of $13 million, or $0.68 per share [10][12] Market Trends - The cannabis sector is experiencing significant growth, with increasing legalization efforts and rising tenant demand, positioning cannabis REITs as one of the best asset classes to watch [3][4] - Each of the highlighted REITs offers a unique approach to accessing the cannabis industry, with IIPR focusing on scale, NLCP on tenant quality, and REFI on high yields through lending [13][14] - The importance of real estate financing in the cannabis supply chain is becoming critical as legalization evolves, making these REITs top candidates for investors seeking yield and diversification [14]

Industry Overview - The cannabis industry is experiencing continuous growth, leading to optimism among investors despite current market conditions [1][2] - There is a lack of sustained volatility in cannabis stocks, which has hindered shareholder profits [2] - Federal legalization is speculated to be a key resolution for the public sector of cannabis companies [2] Company Highlights - **GrowGeneration Corp.** operates retail hydroponic and organic gardening stores in the U.S. and has entered a distribution agreement with V1 Solutions for its products in the EU and Costa Rica [4] - **Hydrofarm Holdings Group, Inc.** manufactures and distributes hydroponics equipment in the U.S. and Canada, reporting a decrease in net sales to $40.5 million from $54.2 million [6][5] - **The Scotts Miracle-Gro Company** reaffirmed its full fiscal year 2025 guidance and is involved in the manufacture and sale of gardening products [8][10] Financial Performance - Hydrofarm's gross profit for Q1 2025 was $6.9 million, with a gross profit margin of 17.0%, down from 20.2% [11] - Adjusted gross profit margin decreased to 21.0% from 23.4% [11] - The company reported a net loss of $14.4 million, an increase from $12.6 million, and an adjusted EBITDA of $(2.4) million compared to $0.3 million [11]

Bad Bet: Cannabis may be legal in Las Vegas, but because it's illegal at the federal level, casinos can't take the risk of permitting it. https://t.co/jnSrYDRCyj https://t.co/jnSrYDRCyj ...

Core Viewpoint - Canopy Growth has significantly underperformed in the cannabis industry, losing 99% of its value over the past five years, with shares trading under $2, making it unattractive for investment [1][11]. Financial Performance - Canopy Growth reported a net revenue of 65 million Canadian dollars for Q4 of fiscal year 2025, down 11% year-over-year, despite a 4% increase in cannabis revenue in Canada [6]. - The company remains deeply unprofitable, with a net loss per share of CA$1.43, worsening from a CA$1.03 loss per share in the previous year [7]. Market Challenges - The cannabis market is heavily regulated, leading to stiff competition and oversupply issues, particularly in Canada and the U.S., where cannabis remains illegal at the federal level [4][10]. - Canopy Growth's international operations, including its subsidiary Storz & Bickel, have not mitigated the negative impact on overall performance [2][6]. Management Outlook - Management has attempted to present a positive outlook by highlighting a 49% reduction in total debt during fiscal year 2025 and aims to achieve positive adjusted EBITDA in the "near term" [8][9]. - Despite potential long-term opportunities in the U.S. cannabis market, the vague nature of management's goals raises skepticism about the company's future profitability [8][9]. Investment Sentiment - The current lack of revenue growth and the uncertain regulatory environment in the U.S. contribute to the view that Canopy Growth is not an attractive investment option [10][11].

Group 1: Company Overview - Tilray Brands went public in 2018 and has since faced significant challenges, with the stock losing nearly all its value despite the U.S. cannabis market exceeding $38 billion last year [1][2] - The company has evolved into a global cannabis business, initially focusing on medical cannabis and later expanding into recreational cannabis, hemp foods, and beverages [4][5] - Tilray currently sells over 40 brands of cannabis products and generated $829 million in sales last year, with projected revenue growth to $893 million this year and $943 million next year [5][6] Group 2: Financial Performance - While sales are not a concern, Tilray has struggled with profitability, reporting a free cash flow of minus $92 million and net losses nearing $250 million last year [7][8] - The U.S. cannabis market is expected to grow over 11% annually through 2030, presenting opportunities for Tilray's diverse product portfolio [6] Group 3: Challenges and Risks - The company has faced operational challenges due to varying legal statuses of cannabis across states in the U.S., leading to pricing pressures and competition from the black market [8] - Tilray's rapid expansion has resulted in a 348% increase in diluted share count since 2018, which negatively impacts revenue and profit distribution among shareholders [9][10] - Despite potential future growth, the stock is unlikely to yield significant returns for investors due to ongoing losses and share dilution [11]